Evidence map›Paper›PMID 42069577›Full record

ArticleCancer cell international2026

Fenofibrate as an anti-cancer treatment: an in vitro study on glioblastoma cells at various oxygen levels and on normal astrocytes.

Yasmine Chokry, Anne-Claire Groo, Sophie Corvaisier, Ons Ben Hadj Hassen, Isis Blanchard, Samuel Valable, Aurélie Malzert-Fréon

Abstract read
In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yasmine ChokryUniversité de Caen Normandie, CNRS, Normandie Univ, ISTCT UMR6030, CYCERON, F-14000 , CAEN, France.ORCID http://orcid.org/0009-0009-4910-7881
Anne-Claire GrooUniversité Caen Normandie, Normandie Univ, CERMN UR4258, F-14000 , Caen, France.ORCID http://orcid.org/0000-0001-6068-5871
Sophie CorvaisierUniversité Caen Normandie, Normandie Univ, CERMN UR4258, F-14000 , Caen, France.ORCID http://orcid.org/0000-0002-4242-6179
Ons Ben Hadj HassenUniversité de Caen Normandie, CNRS, Normandie Univ, ISTCT UMR6030, CYCERON, F-14000 , CAEN, France.ORCID http://orcid.org/0009-0001-7921-0857
Isis BlanchardUniversité de Caen Normandie, CNRS, Normandie Univ, ISTCT UMR6030, CYCERON, F-14000 , CAEN, France.
Samuel Valable *Université de Caen Normandie, CNRS, Normandie Univ, ISTCT UMR6030, CYCERON, F-14000 , CAEN, France. samuel.valable@cnrs.fr.ORCID http://orcid.org/0000-0003-0355-0270
Aurélie Malzert-Fréon *Université Caen Normandie, Normandie Univ, CERMN UR4258, F-14000 , Caen, France. aurelie.malzert-freon@unicaen.fr.ORCID http://orcid.org/0000-0001-6023-1861

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fenofibrate, an active pharmaceutical ingredient (API) of the fibrate class approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypercholesterolemia and hyperlipidemia, has emerged as a promising candidate for repurposing in cancer. Indeed, beyond its lipid-lowering effects, fenofibrate has demonstrated antitumor properties, including antiproliferative and cytotoxic effects in normoxia (21% O

Indexed as

CytostaticityCytotoxicityFenofibrateGlioblastomaHypoxia

Identifiers

PMID42069577
PMCPMC13289253

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.